Abstract | PURPOSE: METHODS: Electronic databases were searched for randomized controlled trials (RCTs) comparing angiogenesis inhibitors with non- angiogenesis inhibitors for NSCLC patients. The extracted data on objective response rates (ORRs), disease control rates (DCRs), progression-free survival (PFS) and overall survival (OS) were pooled. Common adverse events (AEs) were also studied. RESULTS: A total of 33 RCTs involving 17,396 patients were included. Compared with non- angiogenesis inhibitors, angiogenesis inhibitors resulted in significant improvement in PFS (HR, 0.81; 95 % CI 0.76-0.85; p < 0.001), OS (HR, 0.95; 95 % CI 0.92-0.98; p = 0.004), ORR (RR, 1.54; 95 % CI 1.37-1.73; p < 0.001) and DCR (RR, 1.18; 95 % CI 1.10-1.27; p < 0.001). The AEs associated with angiogenesis inhibitors were generally predictable and manageable. CONCLUSION:
|
Authors | Shaodong Hong, Min Tan, Shouzheng Wang, Shengyuan Luo, Yue Chen, Li Zhang |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 141
Issue 5
Pg. 909-21
(May 2015)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 25373315
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Indazoles
- Indoles
- Phenylurea Compounds
- Piperidines
- Pyrimidines
- Pyrroles
- Quinazolines
- Sulfonamides
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Niacinamide
- Bevacizumab
- pazopanib
- Sorafenib
- ramucirumab
- Receptors, Vascular Endothelial Growth Factor
- cediranib
- Sunitinib
- vandetanib
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Bevacizumab
- Carcinoma, Non-Small-Cell Lung
(drug therapy, metabolism, pathology)
- Disease-Free Survival
- Hemorrhage
(chemically induced)
- Humans
- Indazoles
- Indoles
(therapeutic use)
- Lung Neoplasms
(drug therapy, metabolism, pathology)
- Niacinamide
(analogs & derivatives, therapeutic use)
- Odds Ratio
- Phenylurea Compounds
(therapeutic use)
- Piperidines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Pyrroles
(therapeutic use)
- Quinazolines
(therapeutic use)
- Randomized Controlled Trials as Topic
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors, metabolism)
- Signal Transduction
(drug effects)
- Sorafenib
- Sulfonamides
(therapeutic use)
- Sunitinib
- Thrombocytopenia
(chemically induced)
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|